Fibrotic diseases, also known as fibrosis, refer to medical conditions characterized by the excessive formation of fibrous connective tissue in various organs. This excess fibrous tissue can lead to organ dysfunction and, in some cases, organ failure. Fibrotic diseases can affect different organs, including the lungs (pulmonary fibrosis), liver (liver fibrosis or cirrhosis), heart (cardiac fibrosis), and kidneys (renal fibrosis), among others.
Access Full Report @ https://www.databridgemarketresearch.com/pt/reports/global-fibrotic-diseases-treatment-market
Data Bridge Market Research analyses that the Global Fibrotic Diseases Treatment Market will grow at a CAGR of 7.0% during the forecast period of 2023 to 2030. The growing burden of fibrotic diseases such as pulmonary fibrotic diseases, hepatic cirrhosis, renal fibrosis, and cutaneous fibrosis is expected to increase demand for effective treatment medications, which will likely boost the market over the forecast period.
Key Findings of the Study
- The global fibrotic diseases treatment market will grow at a CAGR of 7.0% during the forecast period of 2023 to 2030.
- The increasing prevalence of fibrotic diseases worldwide, driven by factors such as aging, obesity, hypertension, and family history, is escalating the demand for treatment, transforming the fibrotic diseases treatment market.
- The rising prevalence of fibrotic conditions such as pulmonary fibrosis, hepatic cirrhosis, renal fibrosis, and cutaneous fibrosis is projected to drive the demand for more efficient treatment drugs. This is anticipated to positively impact the market throughout the forecast period, as healthcare needs for these conditions continue to grow.
- The Asia-Pacific region is expected to dominate the global fibrotic diseases treatment market from 2023 to 2030, driven by significant technological advancements in developing areas.
Technological advancement in the treatment of fibrosis diseases is expected to drive the market's growth rate
Technological advancements have revolutionized the treatment of fibrotic diseases. Novel diagnostic tools, such as advanced imaging techniques and biomarker identification, enable early disease detection. With its tailored treatment regimens, precision medicine maximizes therapeutic effectiveness while minimizing side effects. The development of cutting-edge therapies such as antifibrotic drugs and gene therapies has shown promising results in reversing or slowing fibrotic processes. Furthermore, telemedicine and digital health platforms enhance patient care and monitoring, ensuring better management of fibrotic diseases in the modern healthcare landscape.
Report Scope and Market Segmentation
|
Report Metric
|
Details
|
|
Forecast Period
|
2023 to 2030
|
|
Base Year
|
2022
|
|
Historic Years
|
2021 (Customizable to 2015-2020)
|
|
Segments Covered
|
Treatment (Medication, Organ Transplantation, Oxygen Therapy, Others), Application (Idiopathic Pulmonary Fibrosis, Hepatic Cirrhosis, Renal Fibrosis, Cutaneous Fibrosis, Others), End User (Hospitals, Specialty Clinics, Academic and Research Institutes, Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Others).
|
|
Countries Covered
|
U.S., Canada, Mexico, Dominican Republic, Jamaica, Panama, Germany, France, U.K., Italy, Spain, Russia, Turkey, Netherlands, Switzerland, Hungary, Lithuania, Austria, Ireland, Norway, Poland, Rest of Europe, Japan, China, India, South Korea, Australia, Singapore, Thailand, Malaysia, Indonesia, Philippines, Vietnam, Taiwan, Rest of Asia-Pacific, Brazil, Ecuador, Chile, Colombia, Venezuela, Argentina, Peru, Curaçao, Paraguay, Uruguay, Trinidad and Tobago, Rest Of South America, South Africa, Saudi Arabia, U.A.E, Egypt, Kuwait, Israel, Bahrain, Rest of Middle East and Africa.
|
|
Market Players Covered
|
Genentech, Inc. (U.S.), C.H. Boehringer Ingelheim International GmbH (Germany), AbbVie Inc. (U.S.), Redx Pharma Plc (U.K), Bristol-Myers Squibb Company (U.S.), BellBrook Labs (U.S.), Enveda Biosciences (U.S.), BioMX (U.S.), Gilead Sciences, Inc. (U.S.), KITHER BIOTECH S.R.L. (Italy), Verona Pharma plc (U.K), Alpine Immune Sciences (U.S.), Intercept Pharmaceuticals, Inc. (U.S.), Pharmaxis Ltd (Australia), Teva Pharmaceutical Industries Ltd. (Israel), Sandoz International GmbH (Germany), Accord Healthcare (U.S.), Camber Pharmaceuticals, Inc. (U.S.)
|
|
Data Points Covered in the Report
|
In addition to the market insights such as market value, growth rate, market segments, geographical coverage, market players, and market scenario the market report curated by the Data Bridge Market Research team includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
|
Segment Analysis:
The global fibrotic diseases treatment market is segmented into treatment, application, end user, and distribution channel.
- On the basis of treatment, the fibrotic diseases treatment market is segmented into medication, organ transplantation, oxygen therapy, and others.
- On the basis of application, the fibrotic diseases treatment market is segmented into idiopathic pulmonary fibrosis, hepatic cirrhosis, renal fibrosis, cutaneous fibrosis, and others.
- On the basis of end user, the fibrotic diseases treatment market is segmented into hospitals, specialty clinics, academic and research institutes, and others.
- On the basis of distribution channel, the fibrotic diseases treatment market is segmented into hospital pharmacy, retail pharmacy, and others.
Major Players
Data Bridge Market Research recognizes the following companies as the major global fibrotic diseases treatment market players in global fibrotic diseases treatment market are Genentech, Inc. (U.S.) C.H. Boehringer Ingelheim International GmbH (Germany) AbbVie Inc. (U.S.) Redx Pharma Plc (U.K) Bristol-Myers Squibb Company (U.S.) BellBrook Labs (U.S.) Enveda Biosciences (U.S.) BioMX (U.S.)
Market Developments
- In May 2023, Boehringer Ingelheim initiated the clinical development of BI 765423, a pioneering IL-11 inhibitor antibody, with a Phase 1 study (NCT05658107) assessing safety, tolerability, and pharmacokinetics in healthy volunteers. Pre-clinical research has shown that this anti-IL-11 medication holds promise in inhibiting and potentially reversing fibrosis in various fibrotic diseases. This development represents a significant step forward in pursuing innovative therapies for fibrotic illnesses, offering hope for improved treatment options.
- In March 2022, Bristol Myers Squibb, a leading pharmaceutical company, announced its acquisition of Turning Point Therapeutics, Inc. for USD 76.00 per share, through a definitive merger agreement. This strategic move garnered unanimous approval from both companies' Boards of Directors and was projected to conclude in the third quarter of 2022. This acquisition has significantly bolstered Bristol Myers Squibb's global presence in the pharmaceutical market, positioning them for enhanced competitiveness and innovation in the industry while potentially expanding their portfolio of life-saving therapies and treatments for patients worldwide.
- In May 2022, the acquisition of Boehringer Ingelheim's digital innovation, BRASS, by ArisGlobal marked a significant move in the pharmaceutical industry. This acquisition allowed ArisGlobal, a global leader in drug safety solutions, to enhance its technology platform, LifeSphere, by integrating BRASS as LifeSphere Clarity. This integration has had a far-reaching impact, contributing to the advancement of pharmacovigilance and patient safety on an industry-wide scale. As a result, ArisGlobal has expanded its clinical diagnostics business presence across various regions worldwide, solidifying its global position in the market.
- In May 2023, Cumberland Pharmaceuticals Inc. announced a significant milestone as the FDA approved their Investigational New Drug Application (IND) for Phase II clinical research focused on patients with Idiopathic Pulmonary Fibrosis (IPF), which is the prevalent form of progressive fibrosing interstitial lung disease. This approval marks a crucial step forward in advancing potential treatments for IPF, offering hope to those affected by this challenging condition. The Phase II research aims to explore therapeutic options further and enhance our understanding of IPF management.
Regional Analysis
Geographically, the countries covered in the global fibrotic diseases treatment market report are the U.S., Canada, Mexico, Dominican Republic, Jamaica, Panama, Germany, France, U.K., Italy, Spain, Russia, Turkey, Netherlands, Switzerland, Hungary, Lithuania, Austria, Ireland, Norway, Poland, Rest of Europe, Japan, China, India, South Korea, Australia, Singapore, Thailand, Malaysia, Indonesia, Philippines, Vietnam, Taiwan, Rest of Asia-Pacific, Brazil, Ecuador, Chile, Colombia, Venezuela, Argentina, Peru, Curaçao, Paraguay, Uruguay, Trinidad and Tobago, Rest Of South America, South Africa, Saudi Arabia, U.A.E, Egypt, Kuwait, Israel, Bahrain, Rest of Middle East and Africa.
As per Data Bridge Market Research analysis:
Asia-Pacific is expected to dominate the global fibrotic diseases treatment market in the forecast period 2023 to 2030
The Asia-Pacific region is expected to dominate the global fibrotic diseases treatment market from 2023 to 2030, driven by the widespread embrace of cutting-edge technologies. This surge in technological adoption is yielding superior results in significantly reduced timeframes. Industries across the region are leveraging innovations in artificial intelligence, automation, and digital transformation, fostering enhanced efficiency and productivity. This transformative shift empowers businesses and economies throughout the Asia-Pacific, positioning the region as the fastest developing hub, with a dynamic and forward-looking approach towards sustainable progress.
For more detailed information about the global fibrotic diseases treatment market report, click here – https://www.databridgemarketresearch.com/pt/reports/global-fibrotic-diseases-treatment-market
